Investor's Business Daily • 3 days ago
What should investors take away from the JPMorgan Healthcare Conference? Sentiment is "cautiously optimistic."
The Wall Street Journal • 3 days ago
The Supreme Court agreed to consider a dispute between Novartis and Amgen that could determine how soon cheaper, copycat versions of biotechnology drugs can be sold to consumers.
Reuters • 3 days ago
The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them. The justices will take up an appeal by Novartis AG of a 2015 federal appeals court decision that prevented the Swiss pharmaceutical company from selling its biosimilar version of California-based Amgen Inc's $1-billion-a-year Neupogen until six months after the Food and Drug Administration approved it. Unlike traditional drugs, biologic drugs cannot be copied exactly to make generic versions.
Bloomberg • 3 days ago
The U.S. Supreme Court agreed to hear a dispute that could help clarify the steps needed to get low-cost alternatives to pricey biotechnology drugs on the market.
Capital Cube • 4 days agoAmgen, Inc. : AMGN-US: Dividend Analysis : November 16th, 2016 (record date) : By the numbers : January 12, 2017
Categories: Yahoo Finance Get free summary analysis Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., AbbVie, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Abbott Laboratories and Johnson & Johnson (PFE-US, BMY-US, GSK-US, CELG-US, GILD-US, ABBV-US, BIIB-US, ALXN-US, ABT-US and JNJ-US). ... Read more (Read more...)
Financial Times • 4 days ago
Under pressure to deliver a new blockbuster medicine, Sanofi, France's biggest drugmaker, bet big on a new class of cholesterol-lowering products with its Praluent treatment. Last week it was dealt a harsh ...
24/7 Wall St. • 4 days ago
As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what the bears have to say about this rally.
CNBC Videos • 3 days ago
Supreme Court is to hear a variety of business-related to cases, including one between Novartis and Amgen over a similar drug. CNBC's Michelle Caruso-Cabrera reports.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||155.26 x 200|
|Ask||162.00 x 400|
|Day's Range||154.89 - 157.21|
|52 Week Range||133.64 - 176.85|
|PE Ratio (TTM)||15.63|
|Earnings Date||Feb 2, 2017|
|Dividend & Yield||4.60 (2.95%)|
|1y Target Est||181.73|